Medigene (FSE: MDG1) is a publicly listed, immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
TCR-T expertise is the foundation for our integrated proprietary end-to-end platform which allows for product enhancement and development technologies.
Company Strategy
Medigene’s strategy is to develop its therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the Company offers selected partners the opportunity to discover and develop additional therapies by accessing Medigene’s proprietary ‘End-to-end’ platform that includes enhancement technologies (like our PD1-41BB costimulatory switch receptor) and optimization technologies (like our Allo-HLA priming).
Focus on T-cell-directed immunotherapies
Focus on T-cell-directed immunotherapies
Roughly 80 employees with expertise in immunotherapy and pharmaceutical development
Roughly 80 employees with expertise in immunotherapy and pharmaceutical development
Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00
Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00